Implementation of a genomic medicine multi-disciplinary team approach for rare disease in the clinical setting: a prospective exome sequencing case series.


Journal

Genome medicine
ISSN: 1756-994X
Titre abrégé: Genome Med
Pays: England
ID NLM: 101475844

Informations de publication

Date de publication:
25 07 2019
Historique:
received: 07 01 2019
accepted: 10 06 2019
entrez: 27 7 2019
pubmed: 28 7 2019
medline: 30 1 2020
Statut: epublish

Résumé

A multi-disciplinary approach to promote engagement, inform decision-making and support clinicians and patients is increasingly advocated to realise the potential of genome-scale sequencing in the clinic for patient benefit. Here we describe the results of establishing a genomic medicine multi-disciplinary team (GM-MDT) for case selection, processing, interpretation and return of results. We report a consecutive case series of 132 patients (involving 10 medical specialties with 43.2% cases having a neurological disorder) undergoing exome sequencing over a 10-month period following the establishment of the GM-MDT in a UK NHS tertiary referral hospital. The costs of running the MDT are also reported. In total 76 cases underwent exome sequencing following triage by the GM-MDT with a clinically reportable molecular diagnosis in 24 (31.6%). GM-MDT composition, operation and rationale for whether to proceed to sequencing are described, together with the health economics (cost per case for the GM-MDT was £399.61), the utility and informativeness of exome sequencing for molecular diagnosis in a range of traits, the impact of choice of sequencing strategy on molecular diagnostic rates and challenge of defining pathogenic variants. In 5 cases (6.6%), an alternative clinical diagnosis was indicated by sequencing results. Examples were also found where findings from initial genetic testing were reconsidered in the light of exome sequencing including TP63 and PRKAG2 (detection of a partial exon deletion and a mosaic missense pathogenic variant respectively); together with tissue-specific mosaicism involving a cytogenetic abnormality following a normal prenatal array comparative genomic hybridization. This consecutive case series describes the results and experience of a multidisciplinary team format that was found to promote engagement across specialties and facilitate return of results to the responsible clinicians.

Sections du résumé

BACKGROUND
A multi-disciplinary approach to promote engagement, inform decision-making and support clinicians and patients is increasingly advocated to realise the potential of genome-scale sequencing in the clinic for patient benefit. Here we describe the results of establishing a genomic medicine multi-disciplinary team (GM-MDT) for case selection, processing, interpretation and return of results.
METHODS
We report a consecutive case series of 132 patients (involving 10 medical specialties with 43.2% cases having a neurological disorder) undergoing exome sequencing over a 10-month period following the establishment of the GM-MDT in a UK NHS tertiary referral hospital. The costs of running the MDT are also reported.
RESULTS
In total 76 cases underwent exome sequencing following triage by the GM-MDT with a clinically reportable molecular diagnosis in 24 (31.6%). GM-MDT composition, operation and rationale for whether to proceed to sequencing are described, together with the health economics (cost per case for the GM-MDT was £399.61), the utility and informativeness of exome sequencing for molecular diagnosis in a range of traits, the impact of choice of sequencing strategy on molecular diagnostic rates and challenge of defining pathogenic variants. In 5 cases (6.6%), an alternative clinical diagnosis was indicated by sequencing results. Examples were also found where findings from initial genetic testing were reconsidered in the light of exome sequencing including TP63 and PRKAG2 (detection of a partial exon deletion and a mosaic missense pathogenic variant respectively); together with tissue-specific mosaicism involving a cytogenetic abnormality following a normal prenatal array comparative genomic hybridization.
CONCLUSIONS
This consecutive case series describes the results and experience of a multidisciplinary team format that was found to promote engagement across specialties and facilitate return of results to the responsible clinicians.

Identifiants

pubmed: 31345272
doi: 10.1186/s13073-019-0651-9
pii: 10.1186/s13073-019-0651-9
pmc: PMC6659244
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

46

Subventions

Organisme : Department of Health
ID : R6–388 / WT 100127
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 204969/Z/16/Z
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/M006824/1
Pays : United Kingdom
Organisme : Arthritis Research UK
ID : 20773
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 090532/Z/09/Z
Pays : United Kingdom
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UP_1502/3
Pays : United Kingdom
Organisme : Medical Research Council
ID : G0900747 91070
Pays : United Kingdom

Références

Am J Hum Genet. 2012 Dec 7;91(6):1095-102
pubmed: 23217327
Bioinformatics. 2012 Nov 1;28(21):2747-54
pubmed: 22942019
Hum Genomics. 2016 Jun 28;10(1):24
pubmed: 27353043
Orphanet J Rare Dis. 2016 Jun 11;11(1):77
pubmed: 27287197
Am J Hum Genet. 2009 Aug;85(2):155-67
pubmed: 19631309
Nat Genet. 2014 Aug;46(8):912-918
pubmed: 25017105
J Allergy Clin Immunol. 2016 Dec;138(6):1722-1725.e6
pubmed: 27543071
Am J Hum Genet. 2005 Jun;76(6):1034-49
pubmed: 15877279
JAMA. 2014 Nov 12;312(18):1880-7
pubmed: 25326637
N Engl J Med. 2018 Nov 29;379(22):2131-2139
pubmed: 30304647
Brain. 2008 Mar;131(Pt 3):747-59
pubmed: 18180250
Lancet. 2015 Apr 4;385(9975):1305-14
pubmed: 25529582
Mol Genet Genomic Med. 2018 May 30;:
pubmed: 29851296
N Engl J Med. 2013 Oct 17;369(16):1502-11
pubmed: 24088041
Nat Genet. 1998 Oct;20(2):157-62
pubmed: 9771708
Cancer Res. 2017 Nov 1;77(21):e31-e34
pubmed: 29092934
Mol Cytogenet. 2017 Aug 23;10:30
pubmed: 28852425
BMC Genomics. 2014 Jun 09;15:449
pubmed: 24912484
JAMA. 2014 Nov 12;312(18):1870-9
pubmed: 25326635
Eur J Hum Genet. 2017 Feb;25(2):176-182
pubmed: 27848944
Nature. 2016 Aug 17;536(7616):285-91
pubmed: 27535533
Nature. 2014 Jun 12;510(7504):288-92
pubmed: 24870241
Cell. 1996 Nov 1;87(3):543-52
pubmed: 8898206
Science. 2016 Dec 23;354(6319):
pubmed: 28008009
Genet Med. 2018 Mar;20(3):320-328
pubmed: 29261176
Nat Genet. 1997 Jan;15(1):62-9
pubmed: 8988170
Genet Med. 2015 May;17(5):405-24
pubmed: 25741868
J Child Neurol. 2010 Jul;25(7):892-7
pubmed: 20097664
Eur J Med Genet. 2017 Oct;60(10):553-558
pubmed: 28774848
Nature. 2015 Mar 12;519(7542):223-8
pubmed: 25533962
J Med Genet. 2002 Aug;39(8):559-66
pubmed: 12161593
Am J Med Genet A. 2016 Mar;170(3):699-702
pubmed: 26494257
JAMA Pediatr. 2017 Sep 1;171(9):855-862
pubmed: 28759686
Am J Med Genet. 1998 Aug 6;78(5):468-73
pubmed: 9714015
Clin Genet. 2016 Mar;89(3):275-84
pubmed: 26283276
Genome Med. 2017 Mar 21;9(1):26
pubmed: 28327206
Am J Hum Genet. 2012 May 4;90(5):925-33
pubmed: 22541558
Brain. 2014 May;137(Pt 5):1323-36
pubmed: 24727571
Nat Genet. 2013 Jul;45(7):825-30
pubmed: 23708187
BMJ. 2018 Apr 24;361:k1687
pubmed: 29691228
Mayo Clin Proc. 2016 Mar;91(3):297-307
pubmed: 26944241
Genome Res. 2011 Jun;21(6):936-9
pubmed: 20980556
Eur J Hum Genet. 2017 Jun;25(6):680-686
pubmed: 28327571
Nat Genet. 2015 Jul;47(7):717-726
pubmed: 25985138
Am J Hum Genet. 2007 May;80(5):988-93
pubmed: 17436254
Eur J Hum Genet. 2015 Aug;23(8):996-1003
pubmed: 25758997
PLoS Genet. 2015 Feb 26;11(2):e1004978
pubmed: 25719903

Auteurs

John Taylor (J)

Oxford Centre for Genomic Medicine, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.

Jude Craft (J)

Oxford Centre for Genomic Medicine, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.

Edward Blair (E)

Oxford Centre for Genomic Medicine, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.

Sarah Wordsworth (S)

Nuffield Department of Population Health, University of Oxford, Oxford, UK.
National Institute for Health Research Biomedical Research Centre, Oxford, UK.

David Beeson (D)

MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.

Saleel Chandratre (S)

Children's Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.

Judith Cossins (J)

MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.

Tracy Lester (T)

Oxford Centre for Genomic Medicine, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.

Andrea H Németh (AH)

Oxford Centre for Genomic Medicine, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
Nuffield Department of Clinical Neurosciences, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.

Elizabeth Ormondroyd (E)

Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, UK.
National Institute for Health Research Biomedical Research Centre, Oxford, UK.

Smita Y Patel (SY)

National Institute for Health Research Biomedical Research Centre, Oxford, UK.
Department of Clinical Immunology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.

Alistair T Pagnamenta (AT)

National Institute for Health Research Biomedical Research Centre, Oxford, UK.
Wellcome Centre for Human Genetics, University of Oxford, Oxford, UK.

Jenny C Taylor (JC)

National Institute for Health Research Biomedical Research Centre, Oxford, UK.
Wellcome Centre for Human Genetics, University of Oxford, Oxford, UK.

Kate L Thomson (KL)

Oxford Centre for Genomic Medicine, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.

Hugh Watkins (H)

Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, UK.
National Institute for Health Research Biomedical Research Centre, Oxford, UK.
Wellcome Centre for Human Genetics, University of Oxford, Oxford, UK.

Andrew O M Wilkie (AOM)

Oxford Centre for Genomic Medicine, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.
National Institute for Health Research Biomedical Research Centre, Oxford, UK.

Julian C Knight (JC)

National Institute for Health Research Biomedical Research Centre, Oxford, UK. julian@well.ox.ac.uk.
Wellcome Centre for Human Genetics, University of Oxford, Oxford, UK. julian@well.ox.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH